Press Release - August 15, 2017
Sernova Retains FronTier Merchant Capital for North America Investor Relations and Marketing
Sernova Engages IR and Marketing Firm as Anticipated
Event-Driven Catalysts Approach
LONDON, ONTARIO – (Marketwire – Tuesday August 15, 2017) – Sernova Corp. (TSX-V: SVA) (OTCQB: SEOVF) (FSE: PSH), a leading clinical stage regenerative medicine company, is pleased to announce that it has engaged FronTier Merchant Capital Group to provide North American investor relations (IR) and strategic marketing services to the financial community and media across North America with the goal to build shareholder value.
Sernova President and CEO Dr. Philip Toleikis commented, "We are pleased to select FronTier Merchant Capital to work with us and serve as our North American investor relations advisors. FronTier’s extensive expertise and experience with impactful media channels and reach into the investment community is expected to greatly enhance the scope and quality of our domestic and US investor relations programs through strategic messaging and investor outreach.”
Using its extensive network, comprised of financial industry professionals, active investors and marketing service providers, FronTier will help to effectively communicate Sernova’s investment potential and corporate vision. With important anticipated catalysts such as near term initiation of a US clinical trial of its Cell Pouch technologies, expanding pharma collaborations, and subsequent expected upgrade of its US listing to a senior exchange, FronTier will assist the company by increasing market awareness through financial market communications, including facilitating in-person introductions for the company with institutional and retail brokers in Canada and throughout the United States, and through media distribution on national television, radio and multiple on-line channels. FronTier has offices in Toronto, Montreal and Calgary.
Under the terms of the engagement, FronTier has been retained for a 12-month period at $80,000 per annum plus direct expenses.
In other developments, Sernova’s board of directors has approved an amendment to the company’s Option Plan & Deferred Share Unit Plan (the “Amended Plan”) to increase the maximum number of Deferred Share Units (“DSUs”) issuable by an additional 660,222 DSUs to a maximum of 1,975,000 DSUs.
Further to the Amended Plan, Sernova has granted 3,735,000 stock options to certain officers, employees and consultants of the company, each such option being exercisable into a common share at a price of $0.25 per share for a period of 10 years, and conditionally granted 900,000 DSUs to its board of directors. The DSU grants are subject to the company obtaining shareholder approval and TSX Venture Exchange approval.
Sernova Corp is a clinical stage leading regenerative medicine Company developing medical technologies for the treatment of chronic debilitating metabolic diseases such as diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. Sernova is developing its Cell Pouch System, an implantable medical device and therapeutic cells (donor, xenogeneic or stem cell derived therapeutic cells). Sernova’s Cell Pouch System, following implantation, is thought to form a vascularized tissue environment for the housing and long-term survival and function of therapeutic cells. Following transplantation of cells it is believed the device, through its design does not result in fibrosis, a common issue with implantable medical devices. It is anticipated that these therapeutic cells may release necessary proteins or hormones missing from the body to treat chronic diseases as an alternative to daily administration of drugs. For more information, visit www.sernova.com
For further information contact: Philip Toleikis, Ph.D., President and CEO Tel: (604) 961-2939 firstname.lastname@example.org email@example.com www.sernova.com
Ray Matthews & Associates Tel: (604) 818-7778 firstname.lastname@example.org www.raymatthews.ca
Forward Looking Information
This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Forward-looking statements, which include our beliefs about the functionality of the Cell Pouch and our cell technologies, clinical trials, collaborations and therapeutic indications are based on the beliefs, estimates and opinions of Sernova’s management on the date such statements were made. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Press Releases from:2018 2017 2016 2015 2014 2013 2012
2011 2010 2009 2008 2007 2006 2005
2004 2003 2002 2001 2000 1999
2014, January 22
Sernova’s Disruptive Regenerative Medicine Technologies Set to Improve the Treatment of Chronic Diseases While Reducing Healthcare CostsLink
2012, July 11
Sernova Corp. developing a tiered approach to the treatment of diabetes
Publisher: Canadian Investor Magazine
Author: Rochelle Emnance
2012, July 30
Feds back local diabetes discovery
Publisher: London Free Press
Author: Norman De Bono
2012, July 30
Federal program pumps $3 million into new, London business
Publisher: The London Free Press
Author: Norman De Bono
2010 July 10
Canada's economic action plan supports business innovators
Publisher: Federal Economic Development Agency for Southern OntarioLink
2007, February 20
"Transplanted cells may protect against diabetes without forced drug use: An interview with Dr. David White"
Author: Julie Ickes and James Finch
2006, October 04
"Sertoli Cells: Mother nature's anti-rejection drug"
Author: James Finch
2006, August 24
"Mass marketing diabetes reversal; novel xeno-transplants may offer new hope for type 1 diabetics"
Author: James Finch
Presentation and Video
July 18, 2018
2018 Financial Report - 2nd Quarter
June 29, 2018
2018 Management Discussion & Analysis (MD&A) - 2nd Quarter
May 28, 2018
March 29, 2018
2018 Financial Report - 1st Quarter
March 29, 2018
2018 Management Discussion & Analysis (MD&A) - 1st Quarter
December 11, 2017
Clearance by FDA of Sernova's US IND
Conference call audio recording
September 11, 2017
Sernova Fact Sheet
Subscribe to Sernova News
All Updates →